Antimicrobial Resistance & AI
at a glance
01 November 2021 to 31 October 2026
European Vaccine Initiative
IMI2 Innovative Medicines Initiative, European Union and EFPIA
9 Mio Euro
Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance
PrIMAVeRa is a European project funded by the Innovative Medicines Initiative 2 (IMI2) dedicated to harnessing the power of big data and AI to steer the fight against antimicrobial resistance.
The project aims to develop an open-source, web-based platform combining mathematical models with a comprehensive epidemiological repository (i.e., with data referring to health and economic outcomes) to predict the impact of vaccines and mAbs on the reduction of AMR. This platform will enable policymakers to reach data-driven decisions regarding prioritisation of specific vaccines and mAbs, informing the strategic allocation of limited resources.
The following main areas will be addressed by PrIMAVeRa in an integrated manner:
Assessment of the availability and quality of published data and existing mathematical models of AMR;
Setting up a comprehensive epidemiological repository;
Development of an improved mathematical models of AMR including cost-effectiveness analyses (CEA);
Establishment of a plan for evaluation of the models in multi-country settings.
A sustainability plan will also be designed by the project partners to ensure long-term access to the project results, including models, beyond the duration of the PrIMAVeRa project.
Ares Genetics GmbH, (Austria), Danmarks Tekniske Universitet, (Denmark), Eberhard Karls Universität Tübingen, (Germany), European Vaccine Initiative (EVI), (Germany), GlaxoSmithKline Biologicals SA (GSK), (Belgium), Hospital of Lithuanian University of Health Sciences Kauno Klinikos, (Lithuania), Institut Pasteur, (France), Institute of Health Carlos III, (Spain), Janssen Vaccines & Prevention B.V., (Netherlands), Life Science Network gGmbH, (Germany), Pasteur Institute of Russia, (Russia), Pfizer, (UK), Public Health England, (UK), Servicio Andaluz de Salud, (Spain), Université Grenoble Alpes, (France), University Medical Center Utrecht (UMC Utrecht), (Netherlands), University of Geneva, (Switzerland), University of Oxford, (UK) and University of Verona, (Italy).
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the authors' view(s) and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.